Anti-F4/80 CAR-T in a mouse tumor model unselectively depleted all TAMs (367), while anti-FRb CAR-T, an M2 marker, allowed for specific targeting of immunosuppressive TAMs and restrained tumor growth (368). This evidence concerns the gene FOLR2 and neoplasm.